Item 1.02 Termination of a Material Definitive Agreement.
On
PRS-080 drug candidate targeting hepcidin in
--------------------------------------------------------------------------------
© Edgar Online, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.71 USD | +1.46% |
|
-5.68% | -40.18% |
05-15 | Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Item 1.02 Termination of a Material Definitive Agreement.
On
PRS-080 drug candidate targeting hepcidin in
--------------------------------------------------------------------------------
© Edgar Online, source
1st Jan change | Capi. | |
---|---|---|
-40.18% | 11.5M | |
+16.45% | 122B | |
+21.96% | 116B | |
+25.24% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.92% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |